LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today urged its stockholders to take no action on the preliminary consent solicitation by Martin Shkreli, his firm, MSMB Capital Management LLC, and their respective affiliates, including Ironman Acquisition, LP and Ironman Acquisition GP, LLC (collectively, "MSMB"). MSMB is proposing to remove six out of the seven current members of AMAG’s Board of Directors and replace them with its own nominees. AMAG’s current Board includes six independent directors with significant financial and management experience in the biotechnology, pharmaceuticals and/or healthcare industries. These directors are working for the best interests of all AMAG stockholders. In addition, upon completion of the proposed merger with Allos Therapeutics, Inc., the new board of the combined company will be comprised of nine directors, five selected by AMAG and four selected by Allos.
